Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425776 | 0.85 | MAPT (0.44) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL5406572 | 0.84 | SLC6A4 (0.53) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL5396979 | 0.82 | SLC6A4 (0.51) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL1585868 | 0.81 | KDM1A (0.44) | SLC6A4HTR7SLC6A3SLC6A2MAPT | |
| SCHEMBL298380 | 0.81 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL30139651 | 0.81 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL30139650 | 0.81 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL23803553 | 0.80 | MAPT (0.49) | MAPTMAPK1CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6076721 | 0.79 | SLC6A4 (0.65) | SLC6A4HTR2AKCNH2HTR1AHTR1D | |
| SCHEMBL16812425 | 0.78 | HTR7 (0.46) | SLC6A4HTR2AKCNH2HTR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| CN-1239472-C | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2006-02-01 | — | — | CN | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | SLC6A4 3455/4885HTR2A 2372/4885KCNH2 1122/4885 |
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885KCNH2 4790/4885 |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | SLC6A4 4503/4885HTR2A 4309/4885KCNH2 4860/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885KCNH2 4790/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A4 3867/4885HTR2A 3482/4885KCNH2 880/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885KCNH2 4790/4885 |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885KCNH2 4790/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A4 3867/4885HTR2A 3482/4885KCNH2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.